Equities analysts expect that Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) will announce earnings per share (EPS) of ($0.75) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Eyegate Pharmaceuticals’ earnings. Eyegate Pharmaceuticals posted earnings of ($1.05) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 28.6%. The firm is expected to report its next earnings report on Tuesday, November 12th.
According to Zacks, analysts expect that Eyegate Pharmaceuticals will report full year earnings of ($1.95) per share for the current fiscal year. For the next year, analysts anticipate that the firm will post earnings of ($3.45) per share. Zacks’ EPS calculations are a mean average based on a survey of research analysts that follow Eyegate Pharmaceuticals.
Eyegate Pharmaceuticals (NASDAQ:EYEG) last issued its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.15.
In related news, major shareholder Armistice Capital Master Fund purchased 605,001 shares of the stock in a transaction dated Monday, September 30th. The stock was purchased at an average price of $3.12 per share, with a total value of $1,887,603.12. 47.50% of the stock is owned by insiders.
A hedge fund recently bought a new stake in Eyegate Pharmaceuticals stock. Susquehanna International Group LLP bought a new position in Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 222,297 shares of the specialty pharmaceutical company’s stock, valued at approximately $53,000. Susquehanna International Group LLP owned about 0.49% of Eyegate Pharmaceuticals as of its most recent filing with the SEC.
Shares of Eyegate Pharmaceuticals stock traded up $0.29 on Tuesday, hitting $4.05. The stock had a trading volume of 14,400 shares, compared to its average volume of 23,695. The stock’s 50-day simple moving average is $3.42 and its two-hundred day simple moving average is $1.32. The stock has a market cap of $15.09 million, a price-to-earnings ratio of -0.90 and a beta of 2.16. Eyegate Pharmaceuticals has a one year low of $2.25 and a one year high of $9.60.
About Eyegate Pharmaceuticals
EyeGate Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing products for treating diseases and disorders of the eye. Its proprietary platform technologies consist of crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S) and iontophoresis drug delivery system.
Recommended Story: How does inflation affect different investments?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eyegate Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.